Predicting Immunotherapy Response

Tumor Immune Dysfunction and Exclusion (TIDE) algorithm was used to infer the clinical response of patients to immunotherapy (23 (link)). High TIDE scores were associated with poorer immunotherapy. In addition, we extracted the IMvigor210 dataset, a group of clinical information on the treatment of urothelial carcinoma by anti-PD-L1 monoclonal antibody (atezolizumab) (24 (link)). The relationship between bladder cancer anti-PD-1 and anti-CTLA4 by Immunophenoscores(IPS) scores and GMII. The IPS score is a predictive score for a patient’s response to anti-PD-1 and anti-ctLA-4 treatments (25 (link)). was downloaded from TCIA database (https://tcia.at/home). These results were used to evaluate the predictive value of GMII for immune checkpoint therapy.